Researchers have determined that an autologous mesenchymal stem cell treatment for progressive multiple sclerosis (MS) is safe and effective. Mesenchymal stem cells [the same type of stem cells found in teeth] have been shown to help support neurons that are damaged by the immune system in patients with MS. Researchers at Hadassah University in Israel have successfully completed a clinical trial that tested the application of patients’ own cells to help repair and support neurons affected by MS. The trial involved obtaining stem cells from patients, culturing and multiplying them in the lab, and infusing them back either intravenously or by direct injection into the spinal cord.
The researchers measured results by comparing the occurrence of treatment failure, as well as MRI imaging of the spinal cord to show lesions, which are typically indicative of neuron damage. In the experimental group, less than 10% of patients experienced disability worsening, versus the 48.4% whose condition worsened in the placebo group. Furthermore, nearly 60% of patients in the experimental group showed no signs of disease activity, meaning they experienced no relapses or lesion progression on the spinal cord. These astonishing results have now propelled this clinical study into Phase II trials.
As treatments emerge, we believe the best stem cells to use will be the patient’s own [autologous stem cells] as this negates the need to find a suitable donor and eliminates the chances of rejection of the transplanted tissue. To learn how to bank your own valuable stem cells to ensure your future health, visit www.StemSave.com or call 877-783-6728 (877-StemSave) today.
The Future of Regenerative Medicine is Now™
To view the full article, click here.